You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 21, 2025

Details for Patent: 11,202,770


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,202,770 protect, and when does it expire?

Patent 11,202,770 protects HETLIOZ LQ and is included in one NDA.

This patent has seventeen patent family members in thirteen countries.

Summary for Patent: 11,202,770
Title:Liquid tasimelteon formulations and methods of use thereof
Abstract: Liquid suspensions of tasimelteon and methods for their use.
Inventor(s): Phadke; Deepak (Olathe, KS), Polymeropoulos; Mihael (Potomac, MD)
Assignee: VANDA PHARMACEUTICALS INC. (Washington, DC)
Application Number:17/119,953
Patent Claim Types:
see list of patent claims
Composition; Compound;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 11,202,770: A Comprehensive Analysis

Introduction

When analyzing a patent, it is crucial to delve into its scope, claims, and the broader patent landscape to understand its validity, enforceability, and potential impact. This article will provide a detailed analysis of the scope and claims of United States Patent 11,202,770, using relevant principles and examples from patent law and practice.

Patent Scope and Claims

Patent scope is a critical aspect of patent law, determining the breadth and depth of protection afforded to an invention. It is often measured through metrics such as independent claim length and independent claim count[3].

Independent Claim Length and Count

Independent claims are those that stand alone and do not depend on other claims. The length and number of these claims can indicate the scope of the patent. Generally, narrower claims with shorter lengths and fewer counts are associated with a higher probability of grant and a shorter examination process[3].

Patent Examination Process

The examination process is pivotal in shaping the final scope of a patent. Here’s how it typically unfolds:

Filing and Initial Review

A patent application, such as the one leading to U.S. Patent 11,202,770, begins with the filing of a provisional or non-provisional application with the U.S. Patent and Trademark Office (USPTO). The application must meet criteria such as novelty, non-obviousness, and enablement[5].

Patent Prosecution

During patent prosecution, the patent examiner reviews the application to determine if the claimed invention is patentable. This process can take several years and often involves amendments to the claims to address examiner objections. If the examiner does not accept the arguments or amended claims, a final rejection may be issued, which can be appealed to an appeal board or the court system[5].

Obviousness-Type Double Patenting (ODP)

ODP is a doctrine that prevents an inventor from securing a second, later-expiring patent for an invention that is not patentably distinct from an earlier patent. This doctrine is crucial in maintaining the integrity of the patent system.

ODP Analysis

In the case of U.S. Patent 11,202,770, if there are earlier patents or applications with overlapping claims, an ODP analysis would be necessary. This analysis considers whether the claims of the later patent are obvious in view of the earlier patent, taking into account any adjustments for Patent Term Adjustment (PTA) and Patent Term Extension (PTE)[1][2].

Patent Term Adjustments and Extensions

Patent term adjustments and extensions can significantly impact the expiration date of a patent.

Patent Term Adjustment (PTA)

PTA is granted to compensate for delays in the patent prosecution process. However, ODP analysis must consider the adjusted expiration date of the patent after any PTA has been applied. This ensures that the patent term is not extended beyond what is legally permissible[1].

Patent Term Extension (PTE)

PTE, on the other hand, is typically granted for delays caused by regulatory review. Unlike PTA, PTE does not affect the ODP analysis directly, as it does not invalidate an otherwise validly obtained PTE[2].

Terminal Disclaimers

Terminal disclaimers are often used to overcome ODP rejections. By disclaiming the term of a later patent beyond the expiration date of an earlier patent, the inventor can avoid the issue of divided ownership and subsequent harassment by multiple assignees[1].

Commercial and Strategic Implications

The scope and claims of a patent have significant commercial and strategic implications.

Licensing and Litigation

Broader patents with unclear or overly broad claims can lead to increased licensing and litigation costs, diminishing the incentives for innovation. Conversely, well-defined and narrow claims can facilitate clearer licensing agreements and reduce the risk of litigation[3].

Market Domination

A patent with a well-defined scope and valid claims can provide a strong foundation for market domination. It allows the patent holder to exclude others from making, using, or selling the invention, thereby protecting market share and revenue streams.

Case Studies and Examples

Real-world cases illustrate the importance of careful analysis of patent scope and claims.

Allergan USA, Inc. v. MSN Laboratories Private Ltd.

In this case, the district court found that claim 40 of U.S. Patent 7,741,356 was invalid due to ODP over claims of later-filed patents. This highlights the importance of considering the filing, issuance, and expiration dates of related patents in ODP analyses[2].

In re Cellect LLC

This case emphasizes that ODP analysis must be performed on patents considering any PTA adjustments and that terminal disclaimers should be evaluated in the context of preventing divided ownership and harassment by multiple assignees[1].

Key Takeaways

  • Patent Scope and Claims: The scope of a patent is crucial and can be measured through metrics like independent claim length and count.
  • ODP Analysis: ODP prevents securing a second, later-expiring patent for an invention not patentably distinct from an earlier patent.
  • Patent Term Adjustments and Extensions: PTA and PTE can impact the expiration date, but ODP analysis must consider adjusted expiration dates.
  • Terminal Disclaimers: Used to overcome ODP rejections and prevent divided ownership.
  • Commercial Implications: Clear and narrow claims can reduce licensing and litigation costs, while well-defined patents can facilitate market domination.

FAQs

  1. What is the purpose of an ODP analysis in patent law?

    • ODP analysis prevents an inventor from securing a second, later-expiring patent for an invention that is not patentably distinct from an earlier patent.
  2. How do Patent Term Adjustments (PTA) affect the expiration date of a patent?

    • PTA compensates for delays in the patent prosecution process and adjusts the expiration date accordingly, but it must be considered in ODP analyses.
  3. What is the role of terminal disclaimers in patent law?

    • Terminal disclaimers are used to overcome ODP rejections by disclaiming the term of a later patent beyond the expiration date of an earlier patent.
  4. How can the scope of a patent be measured?

    • The scope can be measured through metrics such as independent claim length and independent claim count.
  5. What are the commercial implications of having a patent with clear and narrow claims?

    • Clear and narrow claims can reduce licensing and litigation costs, facilitating clearer agreements and reducing the risk of litigation.

Sources

  1. In re Cellect LLC, United States Court of Appeals for the Federal Circuit, August 28, 2023.
  2. Allergan USA, Inc. v. MSN Laboratories Private Ltd., United States Court of Appeals for the Federal Circuit, August 13, 2024.
  3. Patent Claims and Patent Scope, SSRN, September 29, 2016.
  4. What Is the Probability of Receiving a US Patent?, Yale Journal of Law and Technology.
  5. Intellectual Property Protection, KU Office of Research.

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 11,202,770

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Vanda Pharms Inc HETLIOZ LQ tasimelteon SUSPENSION;ORAL 214517-001 Dec 1, 2020 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,202,770

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2020400065 ⤷  Try for Free
Canada 3161975 ⤷  Try for Free
Chile 2022001546 ⤷  Try for Free
China 114727978 ⤷  Try for Free
Colombia 2022009691 ⤷  Try for Free
European Patent Office 4072542 ⤷  Try for Free
Israel 292492 ⤷  Try for Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.